Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment

Vincristine treatment is often the cause of peripheral neuropathy, usually reversible after the discontinuation of treatment or dose reduction.1 There are several reports of acute neurotoxicity caused by the vincristine treatment of patients with hereditary motor and sensory neuropathy (Charcot-Marie-Tooth disease type 1A [CMT-1A]).2 Hereditary neuropathy with liability to pressure palsies (HNPP) is an inherited recurrent focal demyelinating neuropathy, characterized by painless nerve palsies at common sites of compression and entrapment of peripheral nerves. The most common cause of HNPP is a DNA deletion of a 1.5 Mb region on chromosome 17p11.2-p12, which includes the peripheral myelin protein (PMP) 22 gene (duplication of which causes CMT-1A).3 We report the case of a 37-year-old man with HNPP, revealed after vincristine treatment for non-Hodgkin lymphoma. A 37-year-old man developed a predominantly diffuse, large T-cell type non-Hodgkin lymphoma of intermediate grade, stage III. The patient received introduction chemotherapy with the cyclophosphamide, doxorubicin, vincristine, and prednisolone regimen, consisting of a total dose of cyclophosphamide 1,500 mg IV, doxorubicin 100 mg IV, and vincristine 2 mg IV, …